Karsenty G, Elzayat E, Delapparent T, et al Botulinum toxin type a injections into the trigon to treat idiopathic overactive bladder do not induce vesico-ureteral reflux. J Urol 3 — Boy S, Schmid M, Reitz A, et al Botulinum toxin injections into the bladder wall — a morphological evaluation of the injection technique using magnetic resonance imaging.
Map of regiments at gettysburg
J Urol 4 Suppl Reitz A, Stöhrer M, Kramer G, et al European experience of cases treated with botulinum toxin type A injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor activity. Schurch B, de Sèze M, Denys P, et al Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled six-month study.
Popat R, Apostolidis A, Kalsi V, et al A comparison between the response of patients with idiopathic and neurogenic detrusor-overactivity to the first intradetrusor injection of botulinum toxin type A. Minerva Urol Nephrol — Karsenty G, Boy S, Reitz A, et al a botulinum toxin type A in the treatment of neurogenic detrusor overactivity incontinence: a prospective randomized study to compare 30 vs 10 injections sites.
Karsenty G, Lindemann G, Reitz A, et al b The effect of repeated injections of botulinum toxin type A on the efficacy of the treatment of neurogenic overactive bladder and the urinary bladder.
Neuromodulation et toxine botulique dans les hyperactivités vésicales neurogènes de l’enfant
Scand J Urol Nephrol — Kuo HC Urodynamic evidence of effectiveness of botulinum toxin typeAinjection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology — Kessler TM, Danuser H, Schumacher M, et al Botulinum toxin type A injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?
Neurourol Urodyn — Toh K, Tow A, Consigliere D Botulinum toxin type A for refractory detrusor overactivity in patients with spinal cord injuries in Asia preliminary results. Hajebrahimi S, Altaweel W, Cadoret J, et al Efficacy of botulinum toxin type A in adults with neurogenic overactive bladder: initial results. Can J Urol — Klaphajone J, Kitisomprayoonkul W, Sriplakit S Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions.
Arch Phys Med Rehabil — Schulte-Baukloh H, Schobert J, Stolze T, et al Efficacy of botulinum toxin type A bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Schulte-Baukloh H, Weiss C, Stolze T, et al Botulinum toxin type A detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction.
Eur Urol —90 Discussion Ann Acad Med Singapore — Grosse J, Kramer G, Stöhrer M Success of repeat detrusor injections of botulinum toxin type A in patients with severe neurogenic detrusor overactivity and incontinence.
Patki P, Arumungam K, Hamid R, et al Day case treatment of resistant neurogenic detrusor overactivity, following spinal cord injury. Ruffion A, Capelle O, Paparel P, et al What is the optimum dose of botulinum toxin type A for treating neurogenic bladder overactivity? BJU Int — Riccabona M, Koen M, Schindler M, et al Botulinum toxin type A injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia.
Ghei M, Maraj BH, Miller R, et al Effects of botulinum toxin type B on refractory detrusor overactivity: a randomized, double blind, placebo controlled and crossover trial. Reitz A, Schurch B Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity.
J Urol MacDonald R, Fink HA, Huckbay C, et al Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects. Spinal Cord 45 8 — Download references.
Correspondence to A. Anticholinergics and bladder augmentation are the standard treatments. In children, the use of these treatments is still uncommon but the first results are as promising as those in adults and no adverse effects have been reported.
In France, there is a need for additionnal randomized, multicenter trials to confirm the benefits of these two procedures in paediatric urology. This is a preview of subscription content, log in to check access. J Urol 1 Pt 1 : 95— Tanagho EA Neuromodulation in the management of voiding dysfunction in children.
J Urol — Boone TB, Roehrborn CG, Hurt G Transurethral intravesical electrotherapy for neurogenic bladder dysfunction in children with myelodysplasia: a prospective, randomized clinical trial.
J Urol 2 Pt 2 : — J Urol 5 : — Urol Clin North Am 32 1 : 59— J Urol 6 : — J Urol 4 Pt 2 : — Eur Urol — N Engl J Med 9 : — BJU International — Urology 59 3 : — Schurch B, Schulte-Baukloh H Botulinum toxin in the treatment of neurogenic bladder in adults and children.
Eur Urol Suppl.